Trial Profile
Therapeutic Option for Hepatitis B and C: a French Cohort
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Peginterferon (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Antivirals; Velpatasvir; Voxilaprevir
- Indications Hepatitis B; Hepatitis C
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms HEPATHER
- 30 Jan 2023 Planned End Date changed from 1 Aug 2022 to 31 Dec 2024.
- 30 Jan 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Dec 2024.
- 30 Jan 2023 Status changed from recruiting to active, no longer recruiting.